Prakriti Budhathoki

Prakriti Budhathoki

Auto-generated profile, based on publicly available information

Prakriti Budhathoki

Central Department of Chemistry, Tribhuvan University, Kathmandu, Kirtipur, Nepal

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in International Journal of Green Energy
Verified
Journal Article
Closed access
GLGanesh Lamichhane
Ganesh Lamichhane
Ashis AcharyaAshis Acharya
Ashis Acharya
Darbin Kumar PoudelDarbin Kumar Poudel
Darbin Kumar Poudel
Babita AryalBabita Aryal
Babita Aryal
Narayan GyawaliNarayan Gyawali
Narayan Gyawali
NPNiranjan Parajuli
Niranjan Parajuli
The field of bioethanol production has seen rapid advancements in the past few decades. Despite the advancements, bioethanol production’s recent trends cannot prove effective and efficient transportation fuel. Fossil fuels, which currently power-ups most energy demands, from nonrenewable energies, meaning it will bring adverse effects to the environment, including ozone layer depletion and global warming. It makes bioethanol the best alternative to fossil fuels, owing to the fact than it is considered carbon-neutral. In some parts of the world, bioethanol is utilized as an alternative fuel by using the lignocellulosic (LC) residues, and prioritizing its production as better feedstocks available could fulfill the void created in the transportation fuel sector. Separate hydrolysis and co-fermentation (SSCF) and Pre-hydrolysis and simultaneous saccharification and co-fermentation (PSSCF) are superior to all techniques to achieve saccharification, hexose, and pentose fermentation in a one-pot reaction. For the feedstock modification, the genome engineering and cell wall modification are advanced methods so far. As of not long ago, there is no cost-effective and financially achievable pretreatment technique for the removal of lignin that could be industrialized to satisfy the worldwide requirement for bioethanol. In this review we provide the present scenario of energy demand and advancement on bioethanol technology and challenges. Mainly, altering the LC biomass composition, the robust enzyme that enables to hydrolyzed and maximum fermentable sugar yield, and effectively fermenting bacteria and yeast, which is genetically engineered for simultaneous fermentation with the high rate, is future stepping research which should be emphasized in the bioethanol industry. Graphical abstract

25 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
Rishab MarahathaRishab Marahatha
Rishab Marahatha
SBSaroj Basnet
Saroj Basnet
Bibek Raj BhattaraiBibek Raj Bhattarai
Bibek Raj Bhattarai
PBPrakriti Budhathoki
Prakriti Budhathoki
Babita AryalBabita Aryal
Babita Aryal
NPNiranjan Parajuli
Niranjan Parajuli
Hypercholesterolemia has posed a serious threat of heart diseases and stroke worldwide. Xanthine oxidase (XO), the rate-limiting enzyme in uric acid biosynthesis, is regarded as the root of reactive oxygen species (ROS) that generates atherosclerosis and cholesterol crystals. β-Hydroxy β-methylglutaryl-coenzyme A reductase (HMGR) is a rate-limiting enzyme in cholesterol biosynthesis. Although some commercially available enzyme inhibiting drugs have effectively reduced the cholesterol level, most of them have failed to meet the requirements of being apt drug candidates. Here, we have carried out an in-silico analysis of secondary metabolites that have already shown good inhibitory activity against XO and HMGR. Out of 118 secondary metabolites reviewed, sixteen molecules inhibiting XO and HMGR were taken based on IC 50 values reported in vitro assays. Further, receptor-based virtual screening was carried out against secondary metabolites using GOLD Protein-Ligand Docking Software , combined with subsequent post-docking, to study the binding affinities of ligands to the enzymes . In-Silico ADMET analysis was carried out to study their pharmacokinetic properties, followed by toxicity prediction through ProTox-II. The molecular docking of amentoflavone (1) (GOLD score 70.54), and ganomycin I (9) (GOLD score 59.61) evinced that the drug has effectively bind at the competitive site of XO and HMGR, respectively. Besides, 6-paradol (3) and selgin (4) could be potential drug candidates to inhibit XO. Likewise, n-octadecanyl-O-α-D-glucopyranosyl(6’→1”)-O-α-D-glucopyranoside (10) could be potential drug candidates to maintain serum cholesterol. In-silico ADMET analysis showed that the sixteen metabolites were optimal within the categorical range in comparison to commercially available XO and HMGR inhibitors, respectively. Toxicity analysis through Protox-II revealed that 6-gingerol (2) , ganoleucoin K (11) , and ganoleucoin Z (12) are toxic for human use. This computational analysis supports earlier experimental evidence towards the inhibition of XO and HMGR by natural products. Further study is necessary to explore the clinical efficacy of these secondary molecules, which might be alternatives for the treatment of hypercholesterolemia. Graphical